New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
17:18 EDTPPHMPeregrine trading down 3% after reporting Q2 earnings
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
14:05 EDTPPHMPatient at UC Davis Medical center tests negative for Ebola, WSJ reports
Subscribe for More Information
January 29, 2015
13:51 EDTPPHMPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
January 25, 2015
13:57 EDTPPHMUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 16, 2015
09:31 EDTPPHMPeregrine announces Ohase II clinical data of bavituximab with sorafenib
Peregrine Pharmaceuticals announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. In this single-center, single-arm, open-label investigator-sponsored trial, 38 patients with advanced HCC received bavituximab weekly and sorafenib twice daily until disease progression or toxicity. Data show that the combination of bavituximab and sorafenib is associated with an improved time to progression of 6.7 months, a disease specific survival of 8.7 months, a disease control rate of 58% and a 4-month progression-free survival of 62%. Two patients achieved a partial response according to Response Evaluation Criteria In Solid Tumors. The secondary endpoint of median overall survival was 6.2 months. The combination of bavituximab and sorafenib was well-tolerated in patients with advanced HCC with no indications of autoimmune adverse events that have been seen with other checkpoint immunotherapies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use